We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Newborns With Jaundice Develop Normally

By HospiMedica staff writers
Posted on 08 May 2006
Newborn babies who are diagnosed with and treated for jaundice are no more likely than other babies to suffer long-term developmental problems, according to a new study.

Researchers from the University of California, San Francisco (UCSF, USA) and Kaiser Permanente's Division of Research (Oakland, CA, USA) compared 140 infants with bilirubin levels of between 25 mg/dl and 30 mg/dl--a level reached by only about 1 in 700 newborns---to more than 400 control infants. More...
The researchers followed the children up to five years of age, measuring intelligence quotient (IQ), performing neurologic exams, and interviewing parents. They found no significant difference between jaundiced and control newborns in IQ or behavior, or in the proportion of children with abnormal neurologic examinations or with neurologic diagnoses. The study was published in the May 4, 2006, issue of the New England Journal of Medicine.

"These are reassuring results,” said Thomas B. Newman, M.D., M.P.H., professor of pediatrics and biostatistics at UCSF and the lead investigator of the study. Our research shows that when severe jaundice is detected and treated properly, we can prevent long-term neurological problems.

Levels of 30 mg/dl or more can lead to a rare condition called kernicterus, which can cause deafness, cerebral palsy, brain damage, or even death. The usual treatment for infants with elevated bilirubin levels (higher than 15 mg/dl) is phototherapy. The baby is exposed to bright light that is absorbed through the skin, altering the bilirubin and making it easier for the baby's liver to get rid of it.



Related Links:
University of California San Francisco
Kaiser Permanente's Division of Research

Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
LED Surgical Lamp
ACEMST35/57
Syringes
Prefilled Saline Flush Syringes
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.